Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strategic modulation to avoid radiation toxicities for brain integrity (SMART-BRAIN).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Encouraging Local Control With Pediatric Spatially Fractionated Radiation Therapy.

Advances in radiation oncology·2026
Same author

Local Control and Survival Outcomes in Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: The Mayo Clinic Experience.

Journal of pediatric hematology/oncology·2026
Same author

Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children's Oncology Group study ACNS0333.

Neuro-oncology pediatrics·2026
Same author

Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma.

Cancer·2026
Same author

Fetal study of soft tissue anomalies and osteocartilage anlagen defects in congenital club foot.

Journal of pediatric orthopedics. Part B·2026

Related Experiment Video

Updated: May 18, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Peritoneal sarcomatosis in pediatric malignancies.

Winston W Huh1, Nancy E Fitzgerald, Anita Mahajan

  • 1Division of Pediatrics, Children's Cancer Hospital of The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Pediatric Blood & Cancer
|September 25, 2012
PubMed
Summary

Peritoneal sarcomatosis (PSC) in children, often caused by desmoplastic small round cell tumors, has poor outcomes. Emerging treatments like cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) show promise for improving remission.

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Related Experiment Videos

Last Updated: May 18, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Area of Science:

  • Pediatric oncology
  • Surgical oncology
  • Medical imaging

Background:

  • Peritoneal sarcomatosis (PSC) involves multiple sarcomatous tumors in the peritoneum.
  • Pediatric PSC commonly includes desmoplastic small round cell tumors (DSRCT) and rhabdomyosarcomas.
  • Traditional treatments (chemotherapy, palliative surgery) yield poor long-term outcomes.

Purpose of the Study:

  • To review clinical characteristics, biologic mechanisms, radiographic features, and therapies for pediatric PSC.
  • To highlight advancements in imaging for disease evaluation.
  • To assess novel treatment strategies for pediatric PSC.

Main Methods:

  • Review of clinical characteristics of pediatric PSC.
  • Analysis of biologic and radiographic features.
  • Evaluation of current and emerging therapeutic options, including surgery and HIPEC.

Main Results:

  • New imaging technologies enhance the assessment of disease extent and peritoneal spread.
  • Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is under investigation.
  • Improved evaluation methods may lead to better treatment stratification.

Conclusions:

  • Pediatric PSC presents unique challenges requiring comprehensive management.
  • Advanced imaging and multimodal therapies, including HIPEC, offer potential for improved outcomes.
  • Further research is needed to optimize treatment protocols for pediatric PSC.